Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 42.2x - 46.6x | 44.4x |
| Selected Fwd P/E Multiple | 34.9x - 38.5x | 36.7x |
| Fair Value | ₹2,004 - ₹2,215 | ₹2,110 |
| Upside | -14.7% - -5.8% | -10.2% |
| Benchmarks | - | Full Ticker |
| Morepen Laboratories Limited | - | NSEI:MOREPENLAB |
| Lupin Limited | - | NSEI:LUPIN |
| Abbott India Limited | - | NSEI:ABBOTINDIA |
| Alembic Pharmaceuticals Limited | - | NSEI:APLLTD |
| Zydus Lifesciences Limited | - | NSEI:ZYDUSLIFE |
| Mankind Pharma Limited | - | NSEI:MANKIND |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| MOREPENLAB | LUPIN | ABBOTINDIA | APLLTD | ZYDUSLIFE | MANKIND | |||
| NSEI:MOREPENLAB | NSEI:LUPIN | NSEI:ABBOTINDIA | NSEI:APLLTD | NSEI:ZYDUSLIFE | NSEI:MANKIND | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 27.2% | 30.2% | 21.7% | 1.1% | 15.7% | 27.0% | ||
| 3Y CAGR | -0.3% | 16.3% | 20.3% | -18.7% | 20.3% | 14.8% | ||
| Latest Twelve Months | 65.5% | 60.2% | 16.5% | 2.5% | 53.4% | 18.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 5.7% | 3.0% | 17.6% | 12.3% | 18.1% | 17.7% | ||
| Prior Fiscal Year | 2.7% | 2.6% | 17.8% | 6.1% | 11.4% | 14.7% | ||
| Latest Fiscal Year | 5.7% | 9.6% | 20.5% | 9.9% | 19.6% | 18.5% | ||
| Latest Twelve Months | 7.1% | 13.0% | 21.4% | 9.4% | 20.4% | 17.5% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 14.1x | 35.4x | 39.9x | 18.2x | 14.1x | 32.1x | ||
| Price / LTM Sales | 1.5x | 8.2x | 10.1x | 2.6x | 3.9x | 8.3x | ||
| LTM P/E Ratio | 21.8x | 62.7x | 47.1x | 27.5x | 19.3x | 47.5x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | 19.3x | 27.5x | 62.7x | |||||
| Historical LTM P/E Ratio | 53.4x | 53.4x | 53.4x | |||||
| Selected P/E Multiple | 42.2x | 44.4x | 46.6x | |||||
| (x) LTM Net Income | 20,414 | 20,414 | 20,414 | |||||
| (=) Equity Value | 861,015 | 906,332 | 951,648 | |||||
| (/) Shares Outstanding | 412.6 | 412.6 | 412.6 | |||||
| Implied Value Range | 2,086.91 | 2,196.75 | 2,306.59 | |||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 2,086.91 | 2,196.75 | 2,306.59 | 2,350.50 | ||||
| Upside / (Downside) | -11.2% | -6.5% | -1.9% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | MOREPENLAB | LUPIN | ABBOTINDIA | APLLTD | ZYDUSLIFE | MANKIND | |
| Value of Common Equity | 27,507 | 1,798,181 | 629,853 | 166,371 | 874,266 | 969,766 | |
| (/) Shares Outstanding | 548.0 | 913.1 | 21.2 | 196.6 | 1,006.2 | 412.6 | |
| Implied Stock Price | 50.20 | 1,969.25 | 29,641.10 | 846.40 | 868.85 | 2,350.50 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 50.20 | 1,969.25 | 29,641.10 | 846.40 | 868.85 | 2,350.50 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |